Letter From the Editor

Endoscopic techniques have become vital to diagnosis and clinical care, and new, specialized techniques are constantly being rolled out. Historically, the review of performance quality of […]

Letter From the Editor

An estimated 48 million Americans experience foodborne illness annually, according to the Centers for Disease Control and Prevention (2011 estimates). Of these, an estimated 128,000 individuals […]

Letter From the Editor

The so-called Information Age, many will agree, has been both a blessing and a curse. Ease of access to healthcare information has enabled individuals to be […]

Letter From the Editor

Statistics on disease prevalence are readily available for most gastrointestinal conditions, but data on the burden of the disease are sometimes lacking. Unfortunately, knowing how many […]

Letter From the Editor

As we approach the beginning of 2013, many promising advances are just over the horizon. In hepatology, a number of new drugs are being developed for […]

Letter From the Editor

When the direct-acting antiviral (DAA) agents boceprevir (Victrelis, Merck) and telaprevir (Incivek, Vertex) were first approved for the treatment of genotype 1 hepatitis C virus (HCV) […]

Letter From the Editor

Just as this issue was being prepared for publication, the US Food and Drug Administration approved a new drug, linaclotide (Linzess, Ironwood Pharmaceuticals/Forest Pharmaceuticals), for the […]

Letter From the Editor

Currently, patients with celiac disease must adhere to a strict gluten-free diet in order to avoid symptoms. In practical terms, this means foregoing many foods that […]

Letter From the Editor

Routine screening to prevent colorectal cancer has been a major focus of attention in recent years, in part because treatment of colorectal cancer is rarely successful […]

Letter From the Editor

While the advent of anti–tumor necrosis factor (anti-TNF) therapy has dramatically improved the treatment of inflammatory bowel disease (IBD), some clinicians remain concerned about the long-term […]

Letter From the Editor

Just as this issue of Gastroenterology & Hepatology was being prepared for publication, the Centers for Disease Control and Prevention announced a major change to their […]

Letter From the Editor

Hepatotoxicity is often a concern when prescribing certain drugs, as serious drug reactions can occur with potentially devastating consequences. While vigilance in this regard is warranted, […]

Letter From the Editor

In many ways, we live by numbers: Weather forecasts tell us what to wear, stock prices tell us how to invest, and digits on a clock […]

Letter From the Editor

Clostridium difficile infection is known to be associated with the use of antibiotics, and a recent announcement by the US Food and Drug Administration (FDA) highlights […]

Letter From the Editor

Drugs that target tumor necrosis factor (TNF) play a major role in the treatment of inflammatory bowel disease (IBD), but many questions about these drugs remain […]

Letter From the Editor

As we celebrate the beginning of 2012, everyone seems to be excited about making a fresh start. For many people, their New Year’s resolution is to […]

Letter from the Editor

For young physicians who are debating which career to pursue, clinical research is often an attractive option. Clinical studies are essential to medicine, and engaging in […]

Letter from the Editor

Recently, I saw a sign stating that only 1 in 4 people infected with hepatitis C virus (HCV) know that they are infected. This advertisement encouraged […]

Letter from the Editor

Given growing concerns about the cost of healthcare, physicians are increasingly having to consider 2 questions: Is this treatment effective? If so, is it cost-effective? While […]

Letter from the Editor

Inflammatory bowel disease (IBD) can cause a number of symptoms, but pain is sometimes one of the most troubling—not only is it common, but it can […]